Gregory Kinney
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 65 | 2026 | 920 | 6.620 |
Why?
| | Smoking | 34 | 2026 | 1472 | 2.140 |
Why?
| | Coronary Artery Disease | 28 | 2025 | 741 | 1.810 |
Why?
| | Tomography, X-Ray Computed | 44 | 2026 | 2730 | 1.720 |
Why?
| | Smokers | 18 | 2025 | 137 | 1.660 |
Why?
| | Pulmonary Emphysema | 14 | 2025 | 275 | 1.490 |
Why?
| | Diabetes Mellitus, Type 1 | 38 | 2025 | 3890 | 1.460 |
Why?
| | Cannabis | 10 | 2025 | 509 | 1.370 |
Why?
| | Forced Expiratory Volume | 28 | 2026 | 449 | 1.290 |
Why?
| | Bronchiectasis | 7 | 2023 | 112 | 0.960 |
Why?
| | Calcinosis | 17 | 2015 | 234 | 0.940 |
Why?
| | Spirometry | 18 | 2026 | 231 | 0.890 |
Why?
| | Lung | 24 | 2026 | 4109 | 0.870 |
Why?
| | Dronabinol | 4 | 2024 | 247 | 0.820 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 547 | 0.800 |
Why?
| | Hyperlipidemias | 2 | 2023 | 122 | 0.790 |
Why?
| | Disease Progression | 29 | 2026 | 2847 | 0.770 |
Why?
| | Middle Aged | 100 | 2026 | 35875 | 0.750 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 210 | 0.750 |
Why?
| | Marijuana Smoking | 3 | 2022 | 250 | 0.740 |
Why?
| | Cannabinoids | 5 | 2024 | 182 | 0.740 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.730 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2168 | 0.670 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2026 | 2583 | 0.650 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 263 | 0.640 |
Why?
| | Female | 121 | 2026 | 78271 | 0.620 |
Why?
| | Volatilization | 1 | 2019 | 52 | 0.620 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.610 |
Why?
| | Risk Factors | 41 | 2025 | 10779 | 0.610 |
Why?
| | Male | 111 | 2026 | 72315 | 0.600 |
Why?
| | Humans | 147 | 2026 | 144759 | 0.600 |
Why?
| | Aged | 55 | 2026 | 25913 | 0.590 |
Why?
| | Coronary Vessels | 8 | 2025 | 251 | 0.560 |
Why?
| | Cohort Studies | 34 | 2026 | 5960 | 0.550 |
Why?
| | Prenatal Exposure Delayed Effects | 4 | 2026 | 675 | 0.540 |
Why?
| | Coronary Disease | 8 | 2025 | 383 | 0.530 |
Why?
| | Marijuana Abuse | 1 | 2019 | 211 | 0.500 |
Why?
| | Genetic Predisposition to Disease | 12 | 2026 | 2363 | 0.480 |
Why?
| | Vascular Calcification | 5 | 2019 | 110 | 0.470 |
Why?
| | Prospective Studies | 30 | 2025 | 7990 | 0.470 |
Why?
| | Genome-Wide Association Study | 11 | 2026 | 1406 | 0.470 |
Why?
| | Air Pollution | 1 | 2019 | 327 | 0.470 |
Why?
| | Risk Assessment | 9 | 2024 | 3671 | 0.450 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 24 | 0.450 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1169 | 0.450 |
Why?
| | Lung Diseases, Interstitial | 4 | 2025 | 660 | 0.440 |
Why?
| | Cigarette Smoking | 3 | 2025 | 99 | 0.440 |
Why?
| | Adult | 58 | 2026 | 40449 | 0.410 |
Why?
| | Quantitative Trait Loci | 2 | 2026 | 374 | 0.410 |
Why?
| | Depression | 5 | 2025 | 1558 | 0.380 |
Why?
| | Vital Capacity | 8 | 2025 | 290 | 0.380 |
Why?
| | Pulmonary Artery | 5 | 2024 | 1134 | 0.350 |
Why?
| | Cannabidiol | 2 | 2024 | 136 | 0.350 |
Why?
| | Atherosclerosis | 4 | 2023 | 409 | 0.340 |
Why?
| | Longitudinal Studies | 10 | 2024 | 2947 | 0.330 |
Why?
| | Biomarkers | 13 | 2025 | 4271 | 0.330 |
Why?
| | Airway Obstruction | 2 | 2024 | 162 | 0.330 |
Why?
| | Emphysema | 2 | 2023 | 100 | 0.320 |
Why?
| | Walk Test | 3 | 2026 | 80 | 0.310 |
Why?
| | Prevalence | 13 | 2025 | 2834 | 0.310 |
Why?
| | Exercise Tolerance | 4 | 2026 | 283 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2026 | 2145 | 0.300 |
Why?
| | Cross-Sectional Studies | 17 | 2026 | 5868 | 0.290 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 17 | 0.290 |
Why?
| | Lipoproteins | 3 | 2016 | 169 | 0.280 |
Why?
| | Marijuana Use | 3 | 2024 | 213 | 0.280 |
Why?
| | Albuminuria | 4 | 2016 | 190 | 0.280 |
Why?
| | Case-Control Studies | 15 | 2025 | 3604 | 0.280 |
Why?
| | Calcium | 7 | 2018 | 1183 | 0.280 |
Why?
| | Proportional Hazards Models | 7 | 2025 | 1325 | 0.270 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2925 | 0.270 |
Why?
| | Metformin | 2 | 2021 | 318 | 0.260 |
Why?
| | Bronchi | 3 | 2022 | 267 | 0.260 |
Why?
| | Bronchodilator Agents | 2 | 2026 | 182 | 0.260 |
Why?
| | Blood Glucose | 7 | 2026 | 2327 | 0.250 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2115 | 0.250 |
Why?
| | Anxiety | 3 | 2025 | 1109 | 0.240 |
Why?
| | Uteroglobin | 1 | 2026 | 30 | 0.240 |
Why?
| | Young Adult | 15 | 2023 | 14105 | 0.240 |
Why?
| | Body Mass Index | 11 | 2024 | 2438 | 0.240 |
Why?
| | Logistic Models | 13 | 2025 | 2117 | 0.230 |
Why?
| | United States | 13 | 2026 | 15966 | 0.230 |
Why?
| | Follow-Up Studies | 12 | 2026 | 5408 | 0.230 |
Why?
| | Monitoring, Intraoperative | 3 | 2010 | 64 | 0.230 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 576 | 0.230 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8265 | 0.220 |
Why?
| | Precision Medicine | 2 | 2026 | 457 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 250 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 78 | 0.220 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 216 | 0.220 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 252 | 0.220 |
Why?
| | Cause of Death | 2 | 2018 | 471 | 0.220 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 28 | 0.220 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 60 | 0.220 |
Why?
| | Antidepressive Agents | 3 | 2019 | 248 | 0.220 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 221 | 0.220 |
Why?
| | Self Administration | 1 | 2025 | 124 | 0.210 |
Why?
| | RNA Splicing | 1 | 2026 | 284 | 0.210 |
Why?
| | Quality of Life | 4 | 2021 | 3185 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 134 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 522 | 0.210 |
Why?
| | Renal Insufficiency | 2 | 2016 | 168 | 0.210 |
Why?
| | Vaping | 1 | 2025 | 66 | 0.210 |
Why?
| | Symptom Flare Up | 2 | 2021 | 37 | 0.200 |
Why?
| | C-Peptide | 1 | 2025 | 189 | 0.200 |
Why?
| | Dyspnea | 5 | 2024 | 251 | 0.200 |
Why?
| | Polysomnography | 1 | 2024 | 235 | 0.190 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 71 | 0.190 |
Why?
| | Fibrinogen | 3 | 2014 | 177 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2025 | 304 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.190 |
Why?
| | Adiponectin | 4 | 2016 | 244 | 0.190 |
Why?
| | Multimorbidity | 1 | 2023 | 63 | 0.190 |
Why?
| | Phenotype | 6 | 2025 | 3162 | 0.180 |
Why?
| | Limit of Detection | 2 | 2019 | 97 | 0.180 |
Why?
| | Organ Size | 5 | 2025 | 463 | 0.180 |
Why?
| | Propofol | 2 | 2021 | 85 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 91 | 0.180 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1782 | 0.180 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.180 |
Why?
| | Cystatin C | 3 | 2011 | 65 | 0.180 |
Why?
| | Cholesterol | 4 | 2011 | 406 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 101 | 0.170 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 73 | 0.170 |
Why?
| | Models, Genetic | 1 | 2024 | 536 | 0.170 |
Why?
| | Artificial Intelligence | 2 | 2023 | 365 | 0.170 |
Why?
| | Protective Agents | 1 | 2021 | 42 | 0.170 |
Why?
| | Walking | 1 | 2026 | 545 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 151 | 0.170 |
Why?
| | Sarcopenia | 1 | 2022 | 91 | 0.170 |
Why?
| | Hand Strength | 2 | 2022 | 144 | 0.170 |
Why?
| | Hallucinogens | 1 | 2023 | 108 | 0.170 |
Why?
| | Self Report | 3 | 2021 | 872 | 0.170 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 304 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2025 | 535 | 0.160 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 114 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2014 | 416 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 518 | 0.160 |
Why?
| | Foraminotomy | 1 | 2020 | 1 | 0.160 |
Why?
| | Muscular Atrophy | 1 | 2021 | 89 | 0.160 |
Why?
| | Paresthesia | 1 | 2020 | 14 | 0.160 |
Why?
| | Hepatitis C | 1 | 2023 | 254 | 0.160 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.160 |
Why?
| | Osteoporosis | 1 | 2022 | 236 | 0.150 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.150 |
Why?
| | Lumbosacral Region | 1 | 2020 | 59 | 0.150 |
Why?
| | Foam Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | Genetic Markers | 2 | 2019 | 331 | 0.150 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2025 | 876 | 0.150 |
Why?
| | Delirium | 1 | 2021 | 104 | 0.150 |
Why?
| | Calibration | 1 | 2019 | 151 | 0.150 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 318 | 0.150 |
Why?
| | Regression Analysis | 6 | 2022 | 1003 | 0.150 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 179 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2019 | 82 | 0.150 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 45 | 0.140 |
Why?
| | Diabetes Complications | 2 | 2010 | 222 | 0.140 |
Why?
| | Surface Properties | 1 | 2019 | 410 | 0.140 |
Why?
| | Multifactorial Inheritance | 3 | 2025 | 202 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1195 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2020 | 760 | 0.140 |
Why?
| | Adipose Tissue | 2 | 2017 | 652 | 0.140 |
Why?
| | Insulin Resistance | 4 | 2017 | 1241 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 198 | 0.130 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 612 | 0.130 |
Why?
| | Drug Overdose | 1 | 2022 | 370 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 293 | 0.130 |
Why?
| | Linear Models | 6 | 2019 | 854 | 0.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2025 | 691 | 0.130 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | Population Surveillance | 1 | 2021 | 485 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2019 | 205 | 0.130 |
Why?
| | Sleep | 1 | 2024 | 901 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2026 | 2608 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1813 | 0.130 |
Why?
| | Evoked Potentials, Somatosensory | 3 | 2015 | 39 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2019 | 377 | 0.130 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 251 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 41 | 0.120 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 16 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 787 | 0.120 |
Why?
| | HIV Infections | 2 | 2023 | 3154 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 307 | 0.120 |
Why?
| | Blood Pressure | 5 | 2023 | 1769 | 0.120 |
Why?
| | Obesity | 4 | 2022 | 3077 | 0.120 |
Why?
| | Pregnancy | 6 | 2026 | 7190 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 225 | 0.120 |
Why?
| | Aortography | 1 | 2015 | 52 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1539 | 0.110 |
Why?
| | Comorbidity | 5 | 2021 | 1658 | 0.110 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6048 | 0.110 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 32 | 0.110 |
Why?
| | Dexmedetomidine | 1 | 2015 | 44 | 0.110 |
Why?
| | Respiratory System | 1 | 2016 | 149 | 0.110 |
Why?
| | Spinal Fusion | 3 | 2020 | 260 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Evoked Potentials, Motor | 2 | 2015 | 50 | 0.110 |
Why?
| | Adiposity | 2 | 2022 | 543 | 0.110 |
Why?
| | Whole Genome Sequencing | 2 | 2026 | 182 | 0.110 |
Why?
| | Respiratory Muscles | 1 | 2014 | 36 | 0.110 |
Why?
| | Evoked Potentials | 1 | 2015 | 128 | 0.110 |
Why?
| | Sex Factors | 5 | 2025 | 2112 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 965 | 0.100 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 180 | 0.100 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 78 | 0.100 |
Why?
| | Body Composition | 4 | 2021 | 706 | 0.100 |
Why?
| | Health Status | 2 | 2022 | 836 | 0.100 |
Why?
| | Machine Learning | 1 | 2019 | 585 | 0.100 |
Why?
| | Heart | 1 | 2017 | 636 | 0.100 |
Why?
| | Haplotypes | 2 | 2025 | 490 | 0.100 |
Why?
| | Spine | 1 | 2015 | 182 | 0.100 |
Why?
| | Up-Regulation | 1 | 2016 | 851 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 592 | 0.100 |
Why?
| | Sex Distribution | 5 | 2014 | 386 | 0.090 |
Why?
| | Brain | 1 | 2025 | 2933 | 0.090 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 243 | 0.090 |
Why?
| | Aorta | 1 | 2015 | 429 | 0.090 |
Why?
| | Incidence | 4 | 2024 | 2879 | 0.090 |
Why?
| | Colorado | 6 | 2021 | 4564 | 0.090 |
Why?
| | Prognosis | 5 | 2024 | 4282 | 0.090 |
Why?
| | Blood Vessels | 1 | 2013 | 171 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 520 | 0.090 |
Why?
| | Time Factors | 7 | 2024 | 7173 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 583 | 0.090 |
Why?
| | Reference Values | 4 | 2023 | 797 | 0.090 |
Why?
| | Haptoglobins | 1 | 2011 | 66 | 0.090 |
Why?
| | Radiography | 4 | 2016 | 844 | 0.080 |
Why?
| | Genotype | 4 | 2024 | 1833 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1980 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2014 | 354 | 0.080 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 75 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2385 | 0.080 |
Why?
| | Electrodiagnosis | 1 | 2010 | 17 | 0.080 |
Why?
| | Adolescent | 6 | 2022 | 22428 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 427 | 0.080 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.080 |
Why?
| | Iliac Artery | 1 | 2010 | 55 | 0.080 |
Why?
| | Coma | 1 | 2009 | 37 | 0.080 |
Why?
| | Meningomyelocele | 1 | 2010 | 61 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 780 | 0.080 |
Why?
| | Alcohol Drinking | 2 | 2009 | 826 | 0.070 |
Why?
| | Facial Nerve | 1 | 2009 | 39 | 0.070 |
Why?
| | Hypertension | 5 | 2015 | 1263 | 0.070 |
Why?
| | Anesthesia, General | 2 | 2021 | 118 | 0.070 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 20 | 0.070 |
Why?
| | Uric Acid | 1 | 2010 | 166 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2017 | 637 | 0.070 |
Why?
| | Aortic Diseases | 1 | 2010 | 124 | 0.070 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 35 | 0.070 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 47 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 1767 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1985 | 0.070 |
Why?
| | Retrospective Studies | 8 | 2021 | 17066 | 0.070 |
Why?
| | Airway Remodeling | 2 | 2021 | 64 | 0.070 |
Why?
| | Odds Ratio | 4 | 2014 | 1075 | 0.070 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2010 | 155 | 0.070 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 102 | 0.070 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 24 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 102 | 0.070 |
Why?
| | Reproducibility of Results | 5 | 2017 | 3409 | 0.070 |
Why?
| | Neurosurgical Procedures | 1 | 2010 | 202 | 0.070 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1495 | 0.070 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 286 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 323 | 0.070 |
Why?
| | Face | 1 | 2009 | 173 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Spinal Cord | 1 | 2010 | 380 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 551 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 479 | 0.060 |
Why?
| | Dietary Fats | 1 | 2009 | 314 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Inflammation | 2 | 2021 | 2878 | 0.060 |
Why?
| | Heart Rate | 1 | 2010 | 855 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 18 | 0.060 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 427 | 0.060 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2026 | 103 | 0.060 |
Why?
| | Iceland | 1 | 2025 | 11 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 375 | 0.060 |
Why?
| | Contraception | 1 | 2008 | 169 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Organ Specificity | 1 | 2026 | 312 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 521 | 0.060 |
Why?
| | Child, Preschool | 4 | 2024 | 11787 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2025 | 6429 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 156 | 0.060 |
Why?
| | Propensity Score | 2 | 2019 | 367 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 439 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 76 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 529 | 0.060 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2025 | 85 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 46 | 0.050 |
Why?
| | Abdominal Wall | 1 | 2004 | 27 | 0.050 |
Why?
| | Protein Interaction Maps | 1 | 2024 | 51 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2024 | 41 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 510 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1694 | 0.050 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 11 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 198 | 0.050 |
Why?
| | Laryngeal Nerves | 1 | 2023 | 7 | 0.050 |
Why?
| | Laryngeal Muscles | 1 | 2023 | 10 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.050 |
Why?
| | HLA Antigens | 1 | 2025 | 225 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Reflex | 1 | 2023 | 69 | 0.050 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 760 | 0.050 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 199 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 338 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 381 | 0.050 |
Why?
| | Infant | 3 | 2025 | 10034 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 282 | 0.050 |
Why?
| | Antigens, CD | 1 | 2005 | 555 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 176 | 0.040 |
Why?
| | Insulin | 3 | 2022 | 2507 | 0.040 |
Why?
| | Blood Platelets | 1 | 2005 | 400 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 323 | 0.040 |
Why?
| | Muscles | 1 | 2022 | 333 | 0.040 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 171 | 0.040 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2021 | 20 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1382 | 0.040 |
Why?
| | Hepacivirus | 1 | 2023 | 243 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 99 | 0.040 |
Why?
| | Plethysmography | 1 | 2021 | 108 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 26 | 0.040 |
Why?
| | Reaction Time | 2 | 2015 | 438 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 448 | 0.040 |
Why?
| | Mice | 3 | 2026 | 18339 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2021 | 144 | 0.040 |
Why?
| | Diskectomy, Percutaneous | 1 | 2020 | 1 | 0.040 |
Why?
| | Animals | 4 | 2026 | 38058 | 0.040 |
Why?
| | Diskectomy | 1 | 2020 | 24 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 106 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 433 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1098 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 556 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 681 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1306 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 965 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1025 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 574 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 222 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 85 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 45 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 40 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 983 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 11679 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 688 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 482 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 710 | 0.030 |
Why?
| | Genomics | 1 | 2023 | 834 | 0.030 |
Why?
| | Europe | 1 | 2019 | 412 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1047 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Systems Biology | 1 | 2018 | 72 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2527 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 478 | 0.030 |
Why?
| | Electroencephalography | 1 | 2021 | 532 | 0.030 |
Why?
| | Electric Impedance | 1 | 2017 | 111 | 0.030 |
Why?
| | Exercise | 1 | 2009 | 2201 | 0.030 |
Why?
| | Electrocardiography | 2 | 2010 | 662 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 316 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2016 | 29 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 338 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1047 | 0.030 |
Why?
| | Michigan | 1 | 2017 | 136 | 0.030 |
Why?
| | Causality | 1 | 2017 | 126 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 965 | 0.030 |
Why?
| | RNA | 1 | 2023 | 940 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 330 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 491 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 42 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 594 | 0.030 |
Why?
| | Cough | 1 | 2016 | 124 | 0.030 |
Why?
| | Automation | 1 | 2015 | 102 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 69 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 330 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 278 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5597 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 614 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1266 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 236 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 790 | 0.030 |
Why?
| | Child | 3 | 2025 | 22633 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 509 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1256 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 217 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 181 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 92 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3863 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 208 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3121 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1289 | 0.020 |
Why?
| | Vascular Stiffness | 1 | 2017 | 486 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 634 | 0.020 |
Why?
| | Laminectomy | 1 | 2010 | 31 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 481 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2029 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5992 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2010 | 30 | 0.020 |
Why?
| | Internal Fixators | 1 | 2010 | 32 | 0.020 |
Why?
| | Thoracic Vertebrae | 1 | 2010 | 79 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 121 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 27 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2010 | 65 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 653 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 23 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 241 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 100 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 139 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 355 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 454 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3333 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 99 | 0.020 |
Why?
| | Scoliosis | 1 | 2010 | 223 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 518 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1837 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2010 | 2919 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 415 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 379 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 208 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 719 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 389 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 304 | 0.010 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 37 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 105 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 403 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 200 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2433 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 684 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 879 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1173 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1257 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2875 | 0.010 |
Why?
| | Risk | 1 | 2003 | 911 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 375 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1339 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1463 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1387 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|